Welcome to the presentation of the half year results 2023

24 July 2023

Agenda

Dirk Lambrecht, CEO

Business review

Financial review

Walter Scherz, CFO

Outlook

Dirk Lambrecht, CEO

Questions and Answers

Dirk Lambrecht, CEO

Walter Scherz, CFO

Clear structure to focus on customer needs and to benefit from the synergy potential

HealthcareIndustrial

SolutionsSolutions

Pharma

Mobility

Medical

Connectors

General Industry

Food & Beverage

Technology & Innovation

Sustainability & Operational Excellence

Finance & Shared Services

3

Datwyler | Half Year Results 2023 | 24 July 2023 | © DATWYLER | www.datwyler.com

Business Areas

Group Functions

Datwyler half year 2023

Temporary negative effects impact profitability

Covid business loss and customers destocking slowed revenue growth, especially in the Healthcare business

Revenue growth by 11.3% to CHF 602.7 million

Organic growth of 5.6% after adjusting for negative currency effects and acquisitions. A 4.7% sustained positive effect thanks to price increases

Profitability decline due to capacity underutilization in the Healthcare business area

EBIT at CHF 60.5 million and EBIT margin at 10.0%

Net result of CHF 32.1 million due to higher financial expenses

Net revenue

in CHFM

EBIT

in CHFM

EBIT margin

in %

Net result

in CHFM

541.6

602.7

72.5

60.5

13.4

10.0

57.4

32.1

HY 2022

HY 2023

4

Datwyler | Half Year Results 2023 | 24 July 2023 | © DATWYLER | www.datwyler.com

Healthcare Solutions

Medical

Pharma

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Dätwyler Holding AG published this content on 24 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 July 2023 02:59:08 UTC.